Jude Fitzgibbon

The paper shows that immune surveillance in germinal centers eliminates premalignant B-cells, but lymphoma-like mutations allow immune escape and progression to lymphoma.

This study identifies relapse-founding cancer persister cells in follicular lymphoma using a mouse model and shows their transcriptional program is conserved in humans, with potential therapeutic targets identified.

This study identifies DEK::NUP214 as an XPO1-dependent transcriptional activator of leukemia genes, showing selective response to XPO1 inhibitors in t(6;9) AML cases.

PAIRWISE predicts effective personalized drug combinations in cancer using deep learning and transcriptome data, achieving high AUROC scores in validation tests.

The paper identifies non-coding mutations in enhancer clusters associated with pancreatic ductal adenocarcinoma and validates their functional impact using computational and experimental methods.

The paper identifies two distinct subgroups of KMT2A-rearranged AML using phosphoproteomics and shows different drug response profiles.

This study identifies DHX34 as a dual regulator of NMD and pre-mRNA splicing, showing its role in hematopoietic differentiation and disease.

This study identifies two genome-wide significant susceptibility loci for acute myeloid leukemia through a meta-analysis of GWAS data.